Filgrastim for the Promotion of Collateral Growth in Patients With CAD

Subcutaneous Delivery of Filgrastim (rG-CSF) for the Promotion of Collateral Growth in Patients With Coronary Artery Disease

The purpose of this study in humans with stable coronary artery disease (CAD) treatable by PCI (percutaneous coronary intervention) is to evaluate the safety and efficacy of subcutaneous delivery of recombinant granulocyte colony stimulating factor rG-CSF (Filgrastim, Neupogen®, Amgen Switzerland) with regard to the promotion of collateral growth.

The purpose of this study in humans with stable coronary artery disease (CAD) treatable by PCI (percutaneous coronary intervention) is to evaluate the safety and efficacy of subcutaneous delivery of recombinant granulocyte colony stimulating factor rG-CSF (Filgrastim, Neupogen®, Amgen Switzerland) with regard to the promotion of collateral growth.

Inclusion Criteria:

• Age > 18 years old
• 1- to 3-vessel coronary artery disease (CAD)
• Stable angina pectoris
• At least 1 stenotic lesion suitable for PCI
• No Q-wave myocardial infarction in the area undergoing CFI measurement
• Written informed consent to participate in the study

Exclusion Criteria:

• Patients admitted as emergencies
• Acute myocardial infarction
• Unstable CAD
• CAD treated best by CABG
• Patients with overt neoplastic disease
• Patients with diabetic retinopathy
• Liver or kidney disease
• Pre-menopausal women